Table 1.
Clinical and virological characteristics of study groups
| Characteristics | Study population n = 55 | |||
|---|---|---|---|---|
| Successfully treated (n = 14) | ART-naive (n = 14) | Elite controllers (n = 13) | Healthy controls (n = 14) | |
| Age (years) [mean ± s.d. (range)] | 46 ± 9 (29–62) | 38 ± 9 (23–52) | 47 ± 7 (40–60) | 46 ± 8 (30–60) |
| Male [n (%)] | 12 (86%) | 13 (93%) | 7 (54%) | 9 (64%) |
| Time since HIV-1 diagnosis (years) [mean ± s.d. (range)] | 9 ± 4 (3–18) | 6 ± 6·5 (0–19) | 13 ± 4 (4–20) | n.a. |
| CD4 T cell count (cells/μl) [mean ± s.d. (range)] | 660·0 ± 244 (403–1177) | 322 ± 183 (3–523) | 624 ± 247 (417–1341) | 988 ± 301·5 (519–1559) |
| CD8 T cell count (cells/μl) [mean ± s.d. (range)] | 816 ± 265 (452–1381) | 844 ± 354 (272–2180) | 596 ± 357 (162–1198) | 459 ± 159 (227–843) |
| CD4 : CD8 ratio [mean ± s.d. (range)] | 0·86 ± 0·32 (0·44–1·51) | 0·4 ± 0·328 (0·01–1·07) | 1·34 ± 0·68 (0·35–2·72) | 2·32 ± 0·85 (1·16–3·97) |
| Viral load (log10 copies/ml) [mean ± s.d. (range)] | <1·6 | 4·6 ± 0·8 (2·89–6·35) | <1·6 | n.a. |
| Time since start of ART (years) [mean ± s.d. (range)] | 7 ± 3 (3–14) | n.a. | n.a. | n.a. |
| Monocyte count (109/l) [mean ± s.d. (range)] | 0·44 ± 0·15 (0·20–0·71) | 0·53 ± 0·22 (0·19–0·91) | 0·52 ± 0·17 (0·26–0·90) | 0·53 ± 0·17 (0·24–0·76) |
| Platelet count (109/l) [mean ± s.d. (range)] | 234·1 ± 51·4 (178–363) | 209·6 ± 55·33 (122–303) | 282 ± 121·6 (144–511) | 246·5 ± 50·2 (145–323) |
| sCD40L (pg/ml) [mean ± s.d. (range)] | 502 ± 625 (92–2165) | 1279 ± 793 (119–3336) | 995 ± 977 (16–3049) | 601 ± 650 (105–2673) |
These include anti-retroviral therapy (ART) successfully treated (ST), ART-naive, elite controllers (EC) and healthy subjects (HS). Results are shown as mean ± standard deviation (s.d.) and (range); n.a. = not applicable.